LU91442I2 - "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" - Google Patents

"Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"

Info

Publication number
LU91442I2
LU91442I2 LU91442C LU91442C LU91442I2 LU 91442 I2 LU91442 I2 LU 91442I2 LU 91442 C LU91442 C LU 91442C LU 91442 C LU91442 C LU 91442C LU 91442 I2 LU91442 I2 LU 91442I2
Authority
LU
Luxembourg
Prior art keywords
varenicline
optionally
pharmaceutically acceptable
salt
acceptable salt
Prior art date
Application number
LU91442C
Other languages
English (en)
Other versions
LU91442I9 (fr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91442(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of LU91442I2 publication Critical patent/LU91442I2/fr
Publication of LU91442I9 publication Critical patent/LU91442I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
LU91442C 1997-12-31 2008-05-21 "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" LU91442I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (fr) 1997-12-31 1998-11-13 Composes azapolycycliques fusionnes avec un aryle

Publications (2)

Publication Number Publication Date
LU91442I2 true LU91442I2 (fr) 2008-07-21
LU91442I9 LU91442I9 (fr) 2018-12-31

Family

ID=22094096

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91442C LU91442I2 (fr) 1997-12-31 2008-05-21 "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"

Country Status (52)

Country Link
US (6) US6410550B1 (fr)
EP (2) EP1659114A3 (fr)
JP (1) JP3550359B2 (fr)
KR (1) KR100408138B1 (fr)
CN (2) CN1324013C (fr)
AP (1) AP1170A (fr)
AR (1) AR017967A1 (fr)
AT (1) ATE386024T1 (fr)
AU (1) AU753389C (fr)
BG (1) BG65058B1 (fr)
BR (2) BR9816186B1 (fr)
CA (1) CA2316921C (fr)
CO (1) CO4810373A1 (fr)
CY (2) CY1107391T1 (fr)
CZ (1) CZ301925B6 (fr)
DE (2) DE122008000038I1 (fr)
DK (1) DK1044189T4 (fr)
DZ (1) DZ2697A1 (fr)
EA (1) EA003190B1 (fr)
EG (1) EG23816A (fr)
ES (1) ES2301210T5 (fr)
FR (1) FR08C0039I2 (fr)
GT (2) GT199800200AA (fr)
HK (1) HK1031878A1 (fr)
HN (1) HN1998000177A (fr)
HR (2) HRP20000445B1 (fr)
HU (2) HU230297B1 (fr)
IL (2) IL136727A0 (fr)
IS (1) IS5514A (fr)
LU (1) LU91442I2 (fr)
MA (1) MA26589A1 (fr)
ME (1) ME00459B (fr)
MY (1) MY118163A (fr)
NL (1) NL300355I2 (fr)
NO (2) NO319115B1 (fr)
NZ (1) NZ504482A (fr)
OA (1) OA11428A (fr)
PA (1) PA8463901A1 (fr)
PE (1) PE20000053A1 (fr)
PL (1) PL209404B1 (fr)
PT (1) PT1044189E (fr)
RS (1) RS50069B (fr)
SA (1) SA99191123B1 (fr)
SG (1) SG102686A1 (fr)
SI (1) SI1044189T2 (fr)
SK (1) SK286886B6 (fr)
TN (1) TNSN98237A1 (fr)
TR (1) TR200001840T2 (fr)
TW (1) TW513412B (fr)
UA (1) UA66825C2 (fr)
WO (1) WO1999035131A1 (fr)
ZA (1) ZA9811911B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
BR0012793A (pt) 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
BR0208992A (pt) * 2001-04-20 2004-04-27 Pfizer Prod Inc Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila
UA73421C2 (en) * 2001-05-14 2005-07-15 Pfizer Prod Inc Cytrate salt 5,8,14-triazatetracyclo[10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaene and a pharmaceutical composition based thereon
ME00466B (fr) * 2001-05-14 2011-10-10 Pfizer Prod Inc Sels de tartrate de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
CA2468705A1 (fr) * 2001-11-29 2003-06-05 Pfizer Products Inc. Sels succiniques de 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques associees
CA2468717A1 (fr) 2001-11-30 2003-06-05 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
NZ532435A (en) * 2001-11-30 2005-04-29 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
WO2003068170A2 (fr) * 2002-02-14 2003-08-21 The Board Of Trustees Of The Leland Stanford Junior University Traitement de denrees alimentaires aux enzymes contre l'enteropathie au gluten
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003294473A1 (en) * 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
DK1565421T3 (da) * 2002-11-20 2008-09-22 Pfizer Prod Inc Fremgangsmåde til fremstilling af indan -1,3-dicarboxylsyre
WO2004048318A1 (fr) * 2002-11-25 2004-06-10 Pfizer Products Inc. Procede ameliore pour la preparation d'indenes 1,3-substitutees
RU2291862C2 (ru) * 2003-01-15 2007-01-20 Пфайзер Продактс Инк. Способ получения арилконденсированных полициклических лактамов
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2004103372A1 (fr) * 2003-05-20 2004-12-02 Pfizer Products Inc. Compositions pharmaceutiques a base de varenicline
PT1638971E (pt) * 2003-06-04 2008-10-23 Pfizer Prod Inc Preparação de quinoxalinas substituídas a partir da dianilina com 2,3-di-hidroxi-1,4-dioxano
CA2533100A1 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle
MXPA06000785A (es) 2003-07-21 2006-04-18 Pfizer Prod Inc Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
US7766018B2 (en) * 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
JP2008531540A (ja) * 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 高純度置換キノキサリンの調製
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP1976495A2 (fr) * 2006-01-06 2008-10-08 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
KR20090005305A (ko) * 2006-03-27 2009-01-13 화이자 프로덕츠 인크. 바레니클린 표준물질 및 불순물 제어
CA2650211A1 (fr) * 2006-04-24 2007-11-01 Prizer Products Inc. Membranes asymetriques pour dispositifs de distribution de medicament
EP2083921A2 (fr) 2006-09-04 2009-08-05 Neurosearch A/S Combinaisons pharmaceutiques contenant un modulateur du recepteur de la nicotine et un facilitateur cognitif
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
EP2136833B1 (fr) * 2007-03-16 2019-05-01 The Board of Trustees of the Leland Stanford Junior University Thérapie enzymatique de combinaison pour la digestion de gluten diététique
WO2009034431A2 (fr) 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
WO2009101185A2 (fr) * 2008-02-15 2009-08-20 Medichem, S.A. Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
US9463190B2 (en) * 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2268639A2 (fr) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Tosylate de varénicline, un intermédiaire dans le procédé de préparation du l-tartrate de varénicline
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2204369A1 (fr) 2008-12-22 2010-07-07 Medichem, S.A. Procédé de préparation de la varénicline et intermédiaires y afférent
KR20110132564A (ko) 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
WO2010143070A2 (fr) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Co-précipités amorphes de tartrate de varénicline
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
US20120172350A1 (en) * 2009-09-11 2012-07-05 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2545054A1 (fr) 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Varénicline de haute pureté ou son sel pharmaceutiquement acceptable sensiblement exempt d'impureté méthylvarénicline
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (fr) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Sels de la varénicline et leurs formes cristallines
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
US20140128606A1 (en) 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
CN110381919A (zh) 2017-03-03 2019-10-25 西梯茜生命工学股份有限公司 含有伐尼克兰或其药学上可接受的盐的包合复合物的口服施用制剂
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (fr) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique à libération contrôlée de varénicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (fr) 2020-08-14 2022-02-17 Almatica Pharma Llc Co-cristal de varénicline et d'acide oxalique, composition pharmaceutique correspondante et méthodes d'utilisation correspondantes
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (fr) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Promédicaments de varénicline
WO2022222019A1 (fr) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Synthèse totale de varénicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (fr) 2021-12-23 2023-01-05 Medichem, S.A. Formulations pharmaceutiques solides de varénicline
EP4241775A1 (fr) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Comprimé de varénicline et son procédé de fabrication
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (fr) † 1995-09-22 1998-07-22 Novo Nordisk A/S Nouveaux composes azacycliques ou azabicycliques a substitution
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
ES2301210T5 (es) * 1997-12-31 2015-05-07 Pfizer Products Inc. Compuestos azapolicíclicos condensados con un arilo
WO1999042461A1 (fr) * 1998-02-23 1999-08-26 Warner-Lambert Company Derives de quinoxaline substitues utilises comme antagonistes du recepteur de l'interleukine-8
EP0955301A3 (fr) * 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
CA2330576A1 (fr) * 1998-04-29 1999-11-04 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
ME00466B (fr) * 2001-05-14 2011-10-10 Pfizer Prod Inc Sels de tartrate de 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
UA73421C2 (en) * 2001-05-14 2005-07-15 Pfizer Prod Inc Cytrate salt 5,8,14-triazatetracyclo[10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaene and a pharmaceutical composition based thereon
CA2468705A1 (fr) * 2001-11-29 2003-06-05 Pfizer Products Inc. Sels succiniques de 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques associees
CA2468717A1 (fr) * 2001-11-30 2003-06-05 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
NZ532435A (en) * 2001-11-30 2005-04-29 Pfizer Prod Inc Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
CA2533100A1 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle

Also Published As

Publication number Publication date
US6887884B2 (en) 2005-05-03
DE69839131T2 (de) 2009-02-05
CA2316921C (fr) 2004-12-07
EG23816A (en) 2007-09-19
EP1044189B2 (fr) 2015-02-25
HUP0100949A3 (en) 2002-12-28
US20020072525A1 (en) 2002-06-13
DE122008000038I1 (de) 2008-11-13
CA2316921A1 (fr) 1999-07-15
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (fr) 2008-02-13
IS5514A (is) 2000-05-26
NZ504482A (en) 2003-01-31
AU9641698A (en) 1999-07-26
DK1044189T3 (da) 2008-05-13
CY2008013I1 (el) 2009-11-04
AU753389C (en) 2007-08-09
SK286886B6 (sk) 2009-07-06
BR9814592B1 (pt) 2010-06-01
US6951938B2 (en) 2005-10-04
ATE386024T1 (de) 2008-03-15
KR20010033823A (ko) 2001-04-25
BG65058B1 (bg) 2007-01-31
SG102686A1 (en) 2004-03-26
EP1659114A2 (fr) 2006-05-24
FR08C0039I1 (fr) 2008-11-14
PA8463901A1 (es) 2000-09-29
CN1285821A (zh) 2001-02-28
ME00459B (me) 2011-10-10
DE69839131D1 (de) 2008-03-27
EA003190B1 (ru) 2003-02-27
YU40300A (sh) 2003-10-31
CN1715280A (zh) 2006-01-04
NL300355I2 (nl) 2008-11-03
SI1044189T1 (sl) 2008-06-30
US20020072524A1 (en) 2002-06-13
CZ301925B6 (cs) 2010-08-04
FR08C0039I2 (fr) 2009-12-18
IL136727A (en) 2006-06-11
IL136727A0 (en) 2001-06-14
HRP20050506A2 (en) 2006-03-31
TW513412B (en) 2002-12-11
HRP20000445B1 (en) 2009-04-30
NO2006016I2 (fr) 2008-10-20
UA66825C2 (uk) 2004-06-15
LU91442I9 (fr) 2018-12-31
US20070275973A1 (en) 2007-11-29
HU230297B1 (hu) 2015-12-28
PT1044189E (pt) 2008-04-22
SI1044189T2 (sl) 2015-05-29
CO4810373A1 (es) 1999-06-30
EP1659114A3 (fr) 2007-01-17
DK1044189T4 (en) 2015-03-30
US6410550B1 (en) 2002-06-25
PL209404B1 (pl) 2011-08-31
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (fr) 1999-07-15
OA11428A (en) 2004-05-03
GT199800200AA (es) 2000-06-07
MA26589A1 (fr) 2004-12-20
NO20003422L (no) 2000-08-29
GT199800200A (es) 2000-06-07
SK9712000A3 (en) 2002-03-05
DE69839131T3 (de) 2015-05-07
US20020111350A1 (en) 2002-08-15
CY1107391T1 (el) 2010-07-28
NO319115B1 (no) 2005-06-20
AU753389B2 (en) 2002-10-17
RS50069B (sr) 2009-01-22
BR9816186B1 (pt) 2009-01-13
ZA9811911B (en) 2000-06-29
DZ2697A1 (fr) 2003-03-29
PL341824A1 (en) 2001-05-07
BG104561A (en) 2001-01-31
NO2006016I1 (no) 2006-11-27
CY2008013I2 (el) 2009-11-04
BR9814592A (pt) 2000-10-17
MY118163A (en) 2004-09-30
JP3550359B2 (ja) 2004-08-04
NL300355I1 (nl) 2008-08-01
HN1998000177A (es) 1999-02-09
HK1031878A1 (en) 2001-06-29
SA99191123B1 (ar) 2006-10-02
AP9801422A0 (en) 1998-12-31
AR017967A1 (es) 2001-10-24
EP1044189A1 (fr) 2000-10-18
CZ20002438A3 (cs) 2002-11-13
HUS1600018I1 (hu) 2018-05-02
KR100408138B1 (ko) 2003-12-01
TR200001840T2 (tr) 2000-12-21
TNSN98237A1 (fr) 2005-03-15
US20020132824A1 (en) 2002-09-19
CN1324013C (zh) 2007-07-04
NO20003422D0 (no) 2000-06-30
JP2002500218A (ja) 2002-01-08
AP1170A (en) 2003-06-30
US6897310B2 (en) 2005-05-24
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
LU91442I2 (fr) &#34;Varénicline, optionnellement sous forme d&#39;un sel pharmaceutiquement acceptable, y compris le sel tartrate&#34;
LU91372I2 (fr) Retapamulin optionnellement sous forme d&#39;un sel pharmaceutiquement acceptable (altargo)
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d&#39;un sel pharmaceutiquement acceptable
LU92407I2 (fr) Afatinib, éventuellement sous la forme d&#39;un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU91306I2 (fr) Mitratapide, optionnellement sous forme d&#39;un sel d&#39;addition acide pharmaceutiquement acceptable (YARVITAN)
LU88842I2 (fr) Nebivolol optionnellement sous forme d&#39;un sel ou d&#39;un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d&#39;un sel pharmaceutiquement, acceptable tel que le sel d&#39;acétate, et d&#39;estrogènes conjugués
LU88809I2 (fr) Lamivudine facultativement sous la forme d&#39;un sel pharmaceutiquement acceptable
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d&#39;un sel, dont le sel de sodium (CONVENIAr)
LU90426I2 (fr) Abacavir facultativement sous la forme d&#39;un sel pharmaceutiquement acceptable ou d&#39;un d-rive y compris le sulfate d&#39;abacavir
LU90468I2 (fr) Zanamivir facultativement sous la forme d&#39;un sel ou d&#39;un derive pharmaceutiquement acceptable
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d&#39;un sel d&#39;addition acide, d&#39;un N-oxyde, d&#39;unester ou d&#39;un sel d&#39;ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
HUP0003972A3 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HK1045646A1 (zh) 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
NO986023L (no) Vannbasert, farmas°ytisk preparat
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l&#39;hydrochlorure de saxagliptine - Onglyza-saxagliptin
ITTO990892A0 (it) Macchina per caffe&#39;.
AU3843600A (en) Bath equipped with water vibrator and therapeutic method using the same
IT1319529B1 (it) Stampo per l&#39;impiego in macchina i.s.
PL341487A1 (en) Plater&#39;s wedge
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
SI1250320T1 (en) Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
NO984736D0 (no) 3-[(1,2,3,4-tetrahydroisokinolin-2-yl)metyl]-8-azabicyklo[3.2.1]oktan-derivater, deres fremstilling og deres anvendelse i terapeutiske midler
SG91250A1 (en) Burnishing head